832695-04-2

Upstream product

• 1150566-13-4 (E)-t-butyl-4-(4-cyano-5-(2-nitrovinyl)thiophen-3-yl)phenyl-carbamate 
• 1150566-14-5 C₁₈H₁₉N₃O₃S 
• 799293-83-7 3-bromo-4-hydroxy-[3,2-c]-thienopyridine 
• 799293-85-9 3-bromo-4-amino-[3,2-c]-thienopyridine 
• 330793-01-6 (4-tert-butoxycarbonylaminophenyl)boronic acid pinacol ester 
• 29064-82-2 3-bromo-4-chloro-[3,2-c]-thienopyridine 

Downstream Products

• 1374036-20-0 C₂₄H₂₀N₆OS 
• 1374036-18-6 C₂₅H₂₁N₅OS 
• 845870-87-3 C₂₅H₂₀N₄O₂S 
• 845871-06-9 C₂₃H₂₁N₅O₂S 
• 837391-30-7 C₂₆H₂₅N₅OS 
• 1227939-87-8 2-(4-(4-amino-3-(4-aminophenyl)thieno[3,2-c]pyridin-7-yl)-1H-pyrazol-1-yl)ethanol 
• 1374036-40-4 C₃₀H₃₀FN₇O₂S 
• 1369413-11-5 C₂₆H₂₃FN₆O₂S 
• 1227939-82-3 ABT-348 
• 1374036-39-1 C₂₈H₂₄FN₇O₂S 
• 1374036-38-0 C₃₀H₃₀FN₇OS 
• 1374036-37-9 C₂₆H₂₃FN₆O₃S₂ 
• 1374036-36-8 C₂₈H₂₇FN₆OS 
• 1374036-35-7 C₂₇H₂₅FN₆OS 

Relevant academic research and scientific papers

Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families

In an effort to identify multi-targeted kinase inhibitors with a novel spectrum of kinase activity, a screen of Abbott proprietary KDR inhibitors against a broad panel of kinases was conducted and revealed a series of thienopyridine ureas with promising activity against the Aurora kinases. Modification of the diphenyl urea and C7 moiety of these compounds provided potent inhibitors with good pharmacokinetic profiles that were efficacious in mouse tumor models after oral dosing. Compound 2 (ABT-348) of this series is currently undergoing Phase I clinical trials in solid and hematological cancer populations.

KINASE INHIBITORS WITH IMPROVED CYP SAFETY PROFILE

Compounds that inhibit protein kinases such as Aurora-kinases and the VEGFR and PDGFR families of kinases, with an improved safety profile due to low CYP3A4 inhibition, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.

Improved synthesis of 3-substituted-4-amino-[3,2-c]-thienopyridines

(Chemical Equation Presented) Two syntheses of 3-substituted-4-amino-[3,2- c]thienopyridines have been developed to replace the standard literature route to these compounds, which uses unattractive conditions involving azide and high temperatures. The fir

Thienopyridine urea inhibitors of KDR kinase

A series of substituted thienopyridine ureas was prepared and evaluated for enzymatic and cellular inhibition of KDR kinase activity. Several of these analogs, such as 2, are potent inhibitors of KDR (10 nM) in both enzymatic and cellular assays. Further

Thienopyridine kinase inhibitors

Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Thienopyridine and furopyridine kinase inhibitors

Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.